149P A phase Ⅰb/Ⅱ trial of surufatinib plus toripalimab and etoposide (E) combined with cisplatin (P) in patients (pts) with untreated advanced small cell lung cancer (SCLC). (December 2022) - Fang, W.F.; Huang, Y.; Yang, Y.; Zhao, Y.; Zhang, Y.; Zhou, T.; Zhao, S.; Yuxiang, M.; Hong, S.D.; Zhao, H.; Zhang, L.